Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A Trial Investigating the Pharmacokinetic Properties of NN5401 in Children, Adolescents and Adults with Type 1 Diabetes
To investigate the total exposure of SIAC in children, adolescents and adult subjects with type 1 diabetes
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A Trial to Test for Bioequivalence between Two NN1250 Formulations in Healthy Subjects
The primary objective is to test for bioequivalence between two formulations of SIBA (IDeg) based on AUCI454,0-120h,SD and Cmax,I454,SD.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk (The Netherlands)
MAJ Il y a 4 ans
Growth hormone treatment of children after IntraUterine Growth Retardation: IUGR-2 study
Not provided at time of registration
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Liraglutide Effect and Action in Diabetes (LEAD-2): Effect on glycaemic control after once daily administration of liraglutide in combination with metformin versus metformin monotherapy versus metformin and glimepiride combination therapy in subjects with type 2 diabetes. A six-month double-blind, double-dummy, randomised, active control, parallel-group, multi-centre, multi-national trial with an 18 months trial extension period
•To assess and compare the effect on glycaemic control (as measured by HbA1c) of once daily administration of three doses of liraglutide in combination with metformin versus metformin monotherapy vers...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Safety and efficacy of turoctocog alfa in prevention and treatment of bleeds in paediatric previously untreated patients with Haemophilia A
To evaluate safety of turoctocog alfa in paediatric previously untreated patients (PUP) with haemophilia A
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efecto de insulina detemir en combinación con liraglutida y metformina en comparación con liraglutida y metformina en sujetos con diabetes tipo 2. Ensayo de 26 semanas, aleatorizado, abierto, de grupos paralelos, multicéntrico, multinacional con una extensión de 26 semanas
To assess and compare the efficacy (as assessed by HbA1c) of insulin detemir in combination with liraglutide and metformin versus liraglutide and metformin in subjects with type 2 diabetes after 26 we...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Effect of liraglutide on body weight in non-diabetic obese subjects or overweight subjects with comorbidities A randomised, double-blind, placebo controlled, parallel group, multi-centre, multinational trial with stratification of subject to either 56 or 160 weeks of treatment based on pre-diabetes status at randomisation
To establish the efficacy of 3.0 mg liraglutide compared to liraglutide placebo in inducing and maintaining weight loss over 56 weeks in obese subjects and overweight subjects with comorbidities T...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and safety of semaglutide versus canagliflozin as add-on to metformin in subjects with type 2 diabetes
To compare the effect of once-weekly (OW) dosing of subcutaneous semaglutide (1.0 mg) versus once-daily dosing of oral canagliflozin (300 mg) on glycaemic control in subjects with type 2 diabetes (T2D...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Efficacy and safety of semaglutide once-weekly versus placebo in drug-naïve subjects with type 2 diabetes Efficacia e sicurezza di semaglutide una volta a settimana verso placebo in pazienti con diabete di tipo 2 mai trattati (Naive)
To demonstrate superiority of once-weekly dosing of two dose levels of semaglutide versus placebo on glycaemic control after 30 weeks of treatment in drug-naïve subjects with type 2 diabetes Dim...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Effect of liraglutide for weight management in children with Prader-Willi Syndrome
To compare the efficacy of liraglutide versus placebo on weight loss in obese paediatric subjects with Prader-Willi syndrome (PWS) at 16 weeks and versus no treatment at 52 weeks
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2
3
4
5
6
7
8
9
10
Suivant